Lonafarnib reduces mortality in children with progeria (cohort study); FDA-approved in 2020. ConfidenceEstablished Level of evidence●●●●●● Approved by a health authority Observed inHuman MissionMap of aging (12 hallmarks) ConceptsGenomic instabilityLonafarnibHutchinson-Gilford progeria syndrome